However, even though TG2 inhibition exhibited significant efficacy, according to a comparison of the transcripts of the placebo/gluten challenge and the gluten challenge/ZED1227-treated group, which showed a transcriptome profile similar to that of the GFD groups, we detected heterogeneity regarding the gluten-induced and IFNγ-dependent cascade of pathogenic events among ZED1227-treated and gluten-challenged individuals with CeD. Here, TGM2 is linked to cranioectodermal dysplasia.